hrt and tirzepatide together linked to greater weight loss on Tirzepatide - Medical Weight Loss

Who should avoid using DSIP

Because tirzepatide (brand name Mounjaro) was only approved by the FDA in mid-2022 for type 2 diabetes, the ability to rigorously analyze its use (on- and off-label) for a broad population of patients with overweight or obesity, not just a subset captured in insurance databases, has the power to greatly improve our understanding of how these agents are being used in every day practice and the effect that theyre having.

Presented for research literature review only Kalkan KT et al

Get the same active ingredients, personalized dosing, and lower cost, without compromising quality or results

It is a natural part of the weight loss process